quinazolines has been researched along with glucagon-like peptide 1 in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (15.79) | 29.6817 |
| 2010's | 16 (84.21) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| El-kholy, W; MacDonald, PE; Targonsky, ED; Tsushima, RG; Wang, X; Wheeler, MB; Xia, F | 1 |
| Mark, M; Tadayyon, M; Thomas, L | 1 |
| Rungby, J | 1 |
| Gerich, J | 1 |
| Bourdel-Marchasson, I; Dejager, S; Schweizer, A | 1 |
| Garber, AJ | 1 |
| Cho, EB; Hwang, JI; Kim, DK; Kim, HY; Moon, MJ; Park, S; Seong, JY | 1 |
| Jermendy, G | 1 |
| Alter, M; Chaykovska, L; Fuchs, H; Heiden, S; Hocher, B; Klein, T; Rahnenführer, J; Runge, F; von Websky, K | 1 |
| Edwards, KL; Irons, BK; Stapleton, MR; Weis, JM | 1 |
| Engelmann-Pilger, K; Frank, S; Klein, T; Linke, A; Mark, M; Pfeilschifter, J; Schürmann, C; Steinmetz, C | 1 |
| Ishikawa, M; Yamada, Y | 1 |
| Cohen, D | 1 |
| Ardestani, A; Dharmadhikari, G; Kerr-Conte, J; Klein, T; Laue, S; Maedler, K; Pattou, F; Schumann, DM; Shah, P | 1 |
| Anastassiadis, E; Diessel, S; Forst, T; Löffler, A; Pfützner, A | 1 |
| Tibaldi, JM | 1 |
| Hansen, G; Hansen, HH; Jelsing, J; Klein, T; Mark, M; Paulsen, S; Vrang, N | 1 |
| Hamaguchi, Y; Kawanami, T; Murase, K; Nagaishi, R; Nomiyama, T; Takahashi, H; Tanabe, M; Tanaka, T; Terawaki, Y; Yanase, T | 1 |
| Agdauletova, S; Daiber, A; Hausding, M; Klein, T; Kröller-Schön, S; Li, H; Mader, M; Mikhed, Y; Münzel, T; Oelze, M; Pfeffer, A; Schulz, E; Stamm, P; Steven, S; Sudowe, S; Welschof, P; Zinßius, E | 1 |
7 review(s) available for quinazolines and glucagon-like peptide 1
| Article | Year |
|---|---|
Inhibition of dipeptidyl peptidase 4 by BI-1356, a new drug for the treatment of beta-cell failure in type 2 diabetes.
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drugs, Investigational; Glucagon-Like Peptide 1; Humans; Insulin-Secreting Cells; Linagliptin; Molecular Structure; Purines; Quinazolines | 2009 |
DPP-4 inhibitors: what may be the clinical differentiators?
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Energy Intake; Gastric Emptying; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Intestinal Mucosa; Linagliptin; Neurons; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2010 |
Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
Topics: Adamantane; Age Factors; Aged; Aging; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Male; Middle Aged; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Vildagliptin | 2011 |
Novel incretin-based agents and practical regimens to meet needs and treatment goals of patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Glucagon-Like Peptide 1; Humans; Incretins; Linagliptin; Male; Middle Aged; Purines; Quinazolines; Randomized Controlled Trials as Topic; Severity of Illness Index; Treatment Outcome | 2011 |
[Incretin-based therapy for treating patients with type 2 diabetes].
Topics: Adamantane; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Therapy, Combination; Exenatide; Gliclazide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hungary; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Metformin; Nitriles; Peptides; Pioglitazone; Purines; Pyrazines; Pyrrolidines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Venoms; Vildagliptin | 2011 |
An update in incretin-based therapy: a focus on dipeptidyl peptidase--4 inhibitors.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Glucagon-Like Peptide 1; Humans; Linagliptin; Male; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Vildagliptin | 2012 |
Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Linagliptin; Liraglutide; Peptides; Piperidines; Purines; Pyrazines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Weight Loss | 2014 |
1 trial(s) available for quinazolines and glucagon-like peptide 1
| Article | Year |
|---|---|
Effect of linagliptin compared with glimepiride on postprandial glucose metabolism, islet cell function and vascular function parameters in patients with type 2 diabetes mellitus receiving ongoing metformin treatment.
Topics: Aged; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Linagliptin; Male; Metformin; Middle Aged; Plasminogen Activator Inhibitor 1; Postprandial Period; Proinsulin; Purines; Quinazolines; Risk Factors; Sulfonylurea Compounds | 2014 |
11 other study(ies) available for quinazolines and glucagon-like peptide 1
| Article | Year |
|---|---|
Antagonism of rat beta-cell voltage-dependent K+ currents by exendin 4 requires dual activation of the cAMP/protein kinase A and phosphatidylinositol 3-kinase signaling pathways.
Topics: Androstadienes; Animals; Blotting, Western; Catalysis; Cell Line; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Electrophysiology; Enzyme Activation; Enzyme Inhibitors; ErbB Receptors; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucose; Insulin; Insulin Secretion; Kinetics; Male; Mice; Peptide Fragments; Peptides; Phosphatidylinositol 3-Kinases; Phosphorylation; Potassium; Precipitin Tests; Protein Precursors; Quinazolines; Rats; Rats, Wistar; Signal Transduction; Time Factors; Transcriptional Activation; Tyrphostins; Up-Regulation; Venoms; Wortmannin | 2003 |
Chronic treatment with the dipeptidyl peptidase-4 inhibitor BI 1356 [(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione] increases basal glucagon-like peptide-1 and improves glycemic contro
Topics: Animals; Diabetes Mellitus; Disease Models, Animal; Female; Glucagon-Like Peptide 1; Glycemic Index; Humans; Hypoglycemic Agents; Linagliptin; Male; Mice; Purines; Quinazolines; Rats; Rats, Zucker; Tumor Cells, Cultured | 2009 |
Insulin contributes to fine-tuning of the pancreatic beta-cell response to glucagon-like peptide-1.
Topics: Animals; Cell Line; ErbB Receptors; Glucagon-Like Peptide 1; Glucose; Insulin; Insulin-Secreting Cells; Isoquinolines; Naphthalenes; Oncogene Protein v-akt; Organophosphonates; Phosphorylation; Quinazolines; Rats; Receptor Cross-Talk; Receptors, AMPA; Tetrazoles; Tyrphostins | 2011 |
Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy.
Topics: Animals; Area Under Curve; Cardiomyopathies; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Gene Expression Regulation; Glomerular Filtration Rate; Glucagon-Like Peptide 1; Heart; Humans; Kidney Failure, Chronic; Linagliptin; Myocardium; Natriuretic Peptide, Brain; Nephrectomy; Piperidines; Purines; Pyrazines; Quinazolines; Rats; Reverse Transcriptase Polymerase Chain Reaction; Sitagliptin Phosphate; Triazoles; Uracil; Uremia | 2011 |
The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob/ob mice.
Topics: Animals; Chemokine CXCL2; Cyclooxygenase 2; Diabetes Mellitus, Experimental; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Epithelial Cells; Female; Glucagon-Like Peptide 1; Inflammation; Keratinocytes; Linagliptin; Macrophage Inflammatory Proteins; Macrophages; Mice; Mice, Inbred C57BL; Mice, Obese; Myofibroblasts; Neutrophils; Purines; Quinazolines; Wound Healing | 2012 |
[Therapeutic use and adverse events of incretin-related drugs].
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Venoms; Vildagliptin | 2012 |
Reports of pancreatitis are 20-30 times more likely with GLP-1 drugs, analysis finds.
Topics: Adamantane; Diabetes Mellitus; Dipeptides; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Linagliptin; Pancreatitis; Purines; Pyrazines; Quinazolines; Sitagliptin Phosphate; Triazoles; United States | 2013 |
The DPP-4 inhibitor linagliptin restores β-cell function and survival in human isolated islets through GLP-1 stabilization.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Cell Survival; Cytokines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Inverse Agonism; Glucagon-Like Peptide 1; Humans; Insulin; Insulin Secretion; Insulin-Secreting Cells; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Linagliptin; Palmitic Acid; Peptide Fragments; Protein Stability; Purines; Pyrazines; Quinazolines; Recombinant Proteins; Sitagliptin Phosphate; Tissue Culture Techniques; Triazoles | 2013 |
The DPP-IV inhibitor linagliptin and GLP-1 induce synergistic effects on body weight loss and appetite suppression in the diet-induced obese rat.
Topics: Animals; Appetite Depressants; Body Weight; Diet, High-Fat; Dietary Sucrose; Dipeptidyl-Peptidase IV Inhibitors; Drug Synergism; Drug Therapy, Combination; Glucagon-Like Peptide 1; Linagliptin; Male; Obesity; Purines; Quinazolines; Rats; Rats, Sprague-Dawley; Weight Loss | 2014 |
Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Hypoglycemic Agents; Linagliptin; Male; Mice, Inbred C57BL; Neointima; Purines; Quinazolines; Vascular System Injuries | 2014 |
Gliptin and GLP-1 analog treatment improves survival and vascular inflammation/dysfunction in animals with lipopolysaccharide-induced endotoxemia.
Topics: Animals; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Endotoxemia; Glucagon-Like Peptide 1; Inflammation; Linagliptin; Lipopolysaccharides; Liraglutide; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidative Stress; Purines; Pyrazines; Quinazolines; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; Sitagliptin Phosphate; Triazoles | 2015 |